Pashtoon M. Kasi, MD, MS, University of Iowa, Iowa City, IA, discusses precision medicine updates presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, including the use of targeted therapies in cholangiocarcinoma, as well as maintenance olaparib as evaluated in the POLO study (NCT02184195). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).